Provided by Tiger Trade Technology Pte. Ltd.

Hoth Therapeutics

0.6900
+0.05007.81%
Post-market: 0.6698-0.0202-2.93%19:58 EDT
Volume:407.56K
Turnover:270.50K
Market Cap:13.20M
PE:-0.86
High:0.6900
Open:0.6324
Low:0.6324
Close:0.6400
52wk High:2.12
52wk Low:0.4894
Shares:19.13M
Float Shares:18.57M
Volume Ratio:0.16
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8041
EPS(LYR):-0.9032
ROE:-148.85%
ROA:-80.32%
PB:3.17
PE(LYR):-0.76

Loading ...

Hoth Therapeutics Rebrands as Rocket One, Shifts to AI

TIPRANKS
·
May 22

Hoth Therapeutics restructures, pivots to AI semiconductors and spintronic computing under Rocket One rebrand

Reuters
·
May 22

BUZZ-U.S. STOCKS ON THE MOVE-T1 Energy, Home Depot, X-Energy

Reuters
·
May 19

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, SiTime Corp, Hoth Therapeutics

Reuters
·
May 19

Hoth Therapeutics Inc - to Change Name to Rocket One and Restructure for AI Semiconductor Focus

THOMSON REUTERS
·
May 19

Hoth Therapeutics Inc - Company to Continue Biotechnology Programs, May Place Assets in Separate Subsidiary

THOMSON REUTERS
·
May 19

Hoth Therapeutics Inc - Rocket One Secures Exclusive Rights to AI Semiconductor and Spintronic Technologies From Vcu

THOMSON REUTERS
·
May 19

Hoth Therapeutics restructures as Rocket One, pivots to AI semiconductor infrastructure

Reuters
·
May 19

Hoth Therapeutics Q1 EPS $(0.17) Up From $(0.27) YoY

Benzinga
·
May 16

Hoth Therapeutics Q1 FY26 net loss narrows to USD 2.69 million

Reuters
·
May 16

Hoth Therapeutics forms space-industry subsidiary Rocket One

Reuters
·
May 07

BRIEF-Hoth Therapeutics Secures European Authorization In Spain

Reuters
·
May 06

Hoth Therapeutics wins Spain authorization for HT-001 Phase 2a trial

Reuters
·
May 06

Hoth Therapeutics Inc - No Treatment-Limiting Adverse Events Observed in Ht-001 Phase 2a Trial

THOMSON REUTERS
·
May 06

Hoth Therapeutics Inc - No Patients Required Dose Reduction or Discontinuation of Egfr Inhibitor Therapy

THOMSON REUTERS
·
May 06

Hoth Therapeutics Secures European Authorization in Spain for Ht-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

THOMSON REUTERS
·
May 06

Hoth Therapeutics Inc - Over 65% of Patients Reported Meaningful Reductions in Pain and Itching in Ht-001 Trial

THOMSON REUTERS
·
May 06

Hoth Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice

TIPRANKS
·
May 05

Hoth Therapeutics risks Nasdaq delisting after shares fall below $1 bid requirement

Reuters
·
May 05

Hoth Therapeutics Resumes At-the-Market Equity Offering Program

TIPRANKS
·
Apr 17